Gilead Sciences Inc

Vir’s Gilead Agreement Adds a Different Funding Model to Its Cancer Pipeline

Gilead’s collaboration gives Vir another route to earn returns from its licensed cancer-drug technology, with the partner taking responsibility for later development. The immediate funding is modest beside Vir’s existing resources, but the allocation of costs and commercial rights differs from its Astellas partnership.